DekaBank Deutsche Girozentrale Purchases 15,119 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

DekaBank Deutsche Girozentrale grew its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 28.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,149 shares of the company’s stock after purchasing an additional 15,119 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in GE HealthCare Technologies were worth $5,450,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Pathway Financial Advisers LLC acquired a new stake in shares of GE HealthCare Technologies in the 1st quarter worth $25,000. BNP Paribas purchased a new stake in GE HealthCare Technologies in the first quarter valued at about $30,000. Sachetta LLC acquired a new stake in GE HealthCare Technologies in the fourth quarter worth about $31,000. Rise Advisors LLC grew its stake in shares of GE HealthCare Technologies by 241.4% during the first quarter. Rise Advisors LLC now owns 338 shares of the company’s stock worth $31,000 after acquiring an additional 239 shares during the last quarter. Finally, Riverview Trust Co acquired a new position in shares of GE HealthCare Technologies during the first quarter valued at about $31,000. 82.06% of the stock is owned by institutional investors and hedge funds.

GE HealthCare Technologies Stock Up 0.2 %

Shares of GEHC opened at $86.79 on Wednesday. The stock’s 50-day moving average price is $83.26 and its 200-day moving average price is $83.31. The company has a quick ratio of 0.82, a current ratio of 1.06 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $39.62 billion, a price-to-earnings ratio of 25.38, a PEG ratio of 3.26 and a beta of 1.17. GE HealthCare Technologies Inc. has a 52 week low of $62.35 and a 52 week high of $94.50.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Wednesday, July 31st. The company reported $1.00 EPS for the quarter, topping the consensus estimate of $0.98 by $0.02. The business had revenue of $4.84 billion for the quarter, compared to analyst estimates of $4.88 billion. GE HealthCare Technologies had a return on equity of 25.26% and a net margin of 8.10%. The business’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.92 EPS. On average, sell-side analysts predict that GE HealthCare Technologies Inc. will post 4.26 EPS for the current year.

GE HealthCare Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 15th. Shareholders of record on Friday, July 19th were issued a $0.03 dividend. The ex-dividend date was Friday, July 19th. This represents a $0.12 dividend on an annualized basis and a yield of 0.14%. GE HealthCare Technologies’s payout ratio is 3.51%.

Insiders Place Their Bets

In other news, CEO Thomas J. Westrick sold 2,750 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $80.78, for a total transaction of $222,145.00. Following the sale, the chief executive officer now directly owns 17,509 shares in the company, valued at approximately $1,414,377.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Stifel Nicolaus assumed coverage on shares of GE HealthCare Technologies in a research note on Tuesday, August 6th. They issued a “buy” rating and a $100.00 target price for the company. The Goldman Sachs Group started coverage on GE HealthCare Technologies in a research report on Thursday, May 30th. They issued a “neutral” rating and a $87.00 target price on the stock. JPMorgan Chase & Co. began coverage on GE HealthCare Technologies in a research report on Monday, September 9th. They set a “neutral” rating and a $90.00 price target for the company. Finally, Redburn Atlantic raised GE HealthCare Technologies to a “strong-buy” rating in a report on Thursday, August 1st. Six analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, GE HealthCare Technologies currently has a consensus rating of “Moderate Buy” and an average target price of $94.58.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.